VIRIDIAN THERAPEUTICS INC. - COMMON STOCK

Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

28 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

14 Nov 2022 07:01:00 By Nasdaq GlobeNewswire

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

14 Nov 2022 06:59:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th

08 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

08 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

22 Oct 2022 14:04:28 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting

12 Oct 2022 08:12:17 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering

25 Aug 2022 16:03:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

17 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

15 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

15 Aug 2022 07:02:00 By Nasdaq GlobeNewswire

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

15 Aug 2022 06:59:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

08 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

23 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in June Investor Conferences

01 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

12 May 2022 16:05:01 By Nasdaq GlobeNewswire